Literature DB >> 16980940

Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance.

Charles C Guo1, Jonathan I Epstein.   

Abstract

Intraductal carcinoma of the prostate (IDC-P) has been described in radical prostatectomies. However, there is limited information as to its histologic features and clinical significance when seen on prostate biopsy. A total of 27 cases of prostate biopsies with only IDC-P (ie no infiltrating cancer anywhere on the biopsy) were studied from the consult files of one of the authors. IDC-P was defined as malignant epithelial cells filling large acini and prostatic ducts, with preservation of basal cells forming either: (1) solid or dense cribriform patterns or; (2) loose cribriform or micropapillary patterns with either marked nuclear atypia (nuclear size 6 x normal or larger) or comedonecrosis. The numbers of cores involved by IDC-P in the biopsies ranged from 1 to 7, with >1 core involved in 17 cases. The architectural patterns of IDC-P were solid (12), dense cribriform (19), loose cribriform (17), and micropapillary (5). More than one pattern was present in 24 of 27 cases. The cytological features frequently observed in IDC-P were marked pleomorphism (18), non-focal comedonecrosis (22), and mitoses (20). Basal cells were observed on regular hematoxylin and eosin stained slides in 14 cases; in all the cases, basal cells were confirmed by immunohistochemical stains for high molecular weight cytokeratin (n=25) and/or p63 (n = 4). After the diagnosis of IDC-P on prostate biopsies, patients were treated by radical prostatectomy (6), radiation (7), hormone (5), combined radiation and hormone (1), or watchful waiting (2). The follow-up information was not available for six patients. The follow-up times ranged up to 4 years with an average of 2.1 years. In all six radical prostatectomy specimens, high-grade infiltrating carcinoma with Gleason score 8 or 9 was present with five cases also revealing prominent IDC-P. Non-focal extraprostatic extension of carcinoma was observed in five of the six prostatectomy cases with two cases also demonstrating vascular invasion. Three of 16 patients who did not receive radical prostatectomy developed bone metastases. Our study indicates that IDC-P on prostate biopsies is frequently associated with high-grade cancer and poor prognostic parameters at radical prostatectomy as well as potentially advanced disease following other therapies. These findings support prior studies that IDC-P represents an advanced stage of tumor progression with intraductal spread of tumor. Consideration should be given to treat patients with IDC-P on biopsy aggressively even in the absence of documented infiltrating cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980940     DOI: 10.1038/modpathol.3800702

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  60 in total

1.  [The 2014 consensus conference of the ISUP on Gleason grading of prostatic carcinoma].

Authors:  G Kristiansen; L Egevad; M Amin; B Delahunt; J R Srigley; P A Humphrey; J I Epstein
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

2.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Authors:  Kosuke Miyai; Mukul K Divatia; Steven S Shen; Brian J Miles; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 3.  Intraductal carcinoma of prostate (IDC-P): from obscure to significant.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

4.  Small cell-like glandular proliferation of prostate: a rare lesion not related to small cell prostate cancer.

Authors:  Oleksandr N Kryvenko; Sean R Williamson; Kiril Trpkov; Nilesh S Gupta; Daniel Athanazio; Martin K Selig; Paul Taylor Smith; Cristina Magi-Galluzzi; Merce Jorda
Journal:  Virchows Arch       Date:  2016-10-14       Impact factor: 4.064

5.  Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.

Authors:  Pedro Isaacsson Velho; John L Silberstein; Mark C Markowski; Jun Luo; Tamara L Lotan; William B Isaacs; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2018-01-25       Impact factor: 4.104

6.  Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Ewout W Steyerberg; Chris H Bangma; Luca Incrocci; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2017-05-19       Impact factor: 7.842

7.  Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.

Authors:  Akiyuki Yamamoto; Masashi Kato; Hirotaka Matsui; Ryo Ishida; Tohru Kimura; Yasuhito Funahashi; Naoto Sassa; Yoshihisa Matsukawa; Osamu Kamihira; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2018-02-03       Impact factor: 3.402

Review 8.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

9.  The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.

Authors:  Masashi Kato; Toyonori Tsuzuki; Kyosuke Kimura; Akihiro Hirakawa; Fumie Kinoshita; Naoto Sassa; Ryo Ishida; Akitoshi Fukatsu; Tohru Kimura; Yasuhito Funahashi; Yoshihisa Matsukawa; Ryohei Hattori; Momokazu Gotoh
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

10.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Authors:  Bo Han; Rohit Mehra; Robert J Lonigro; Lei Wang; Khalid Suleman; Anjana Menon; Nallasivam Palanisamy; Scott A Tomlins; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2009-05-01       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.